Company profile
GPCR Therapeutics, Inc.
Privately held: no public share price (Seoul-based clinical-stage biopharma targeting GPCR heteromers in oncology (founded 2013). Confirmed private (PitchBook/CB Insights). Note: the ticker "GPCR" on Nasdaq belongs to an unrelated company, Structure Therapeutics Inc. -- not to be confused with this entity. Sources: https://clinicaltrials.gov/study/NCT01018979 ; https://api.gleif.org/api/v1/lei-records/2549000CDYS5YH6XDR52 ; https://api.gleif.org/api/v1/lei-records/984500EC7LEQEU100570 ; https://api.gleif.org/api/v1/lei-records/254900ESD9GZFY66OR92 ; https://api.gleif.org/api/v1/lei-records/549300NIGKDV9203Q946 ; https://api.gleif.org/api/v1/lei-records/5493007DSIFXCC6J0N24 Entity resolved by asset-pipeline-v2.)
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
Burixafor (TG-0054)No recent activity | Phase 3 | CXCR4Small molecule | Multiple Myeloma |
| Phase 2 | CXCR4Small molecule | Multiple Myeloma |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.